Bionexus Gene Lab Corp. — Form 10-Q Summary
Business Context and Reporting Period
This unaudited quarterly report covers the three months ended March 31, 2024, compared with the same period in 2023. BioNexus is a Wyoming holding company with Malaysian subsidiaries MRNA Scientific Sdn. Bhd., which develops and provides molecular and RNA-based screening services, and Chemrex Corporation Sdn. Bhd., an industrial chemicals wholesaler. The company is listed on Nasdaq under BGLC and had 17,667,663 common shares outstanding as of May 8, 2024.
Financial Performance and Position
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Revenue | $2.382 million | $2.377 million | Up 0.2% |
| Gross profit | $365,031 | $368,897 | Down 1.0% |
| Gross margin | 15.3% | 15.5% | Down approximately 0.2 percentage points |
| Loss from operations | $79,028 | $50,631 | Loss increased 56.1% |
| Net loss | $103,757 | $69,066 | Loss increased 50.2% |
| Comprehensive loss | $313,665 | $108,105 | Loss increased substantially |
| Basic and diluted loss per share | $0.018 | $0.007 | Loss per share increased |
| Net cash used in operating activities | $34,442 | $116,518 | Use decreased |
- Chemrex generated $2.379 million, or 99.9%, of consolidated revenue. MRNA Scientific generated $3,165, down 57.4% because of RNA machine breakdowns.
- Other income increased to $201,847 from $117,344, primarily from dividends, fair-value gains on investments, recoveries of expected credit losses, interest and foreign exchange gains.
- General and administrative expense increased 20.3% to $645,906, including higher receivable-loss provisions, staffing, professional fees, director fees, travel and Nasdaq-related costs.
- Cash and cash equivalents were $5.832 million at March 31, 2024, consisting of $2.489 million in bank balances and $3.343 million in fixed deposits. Cash decreased by $97,155 during the quarter, including a $111,030 foreign-currency translation adjustment.
- Working capital was $6.189 million, compared with $6.416 million at December 31, 2023. Total assets were $11.161 million and total liabilities were $1.817 million.
- The filing reports no conventional debt or borrowings. Liabilities primarily comprised $1.429 million of trade payables, $214,735 of other payables and accrued liabilities, $40,129 owed to directors, and $121,354 of operating lease liabilities.
- Other investments totaled $1.656 million at quarter-end. The company acquired $174,247 of investments, received $211,344 from investment disposals and recognized a $40,488 fair-value gain during the quarter.
Material Changes Versus the Prior Comparable Period
- Revenue was essentially flat, while gross profit declined modestly because Chemrex sold newly purchased inventory at higher prices.
- Operating losses widened as administrative expenses rose faster than gross profit. The holding company’s expenses increased to $149,422 from $107,440, and MRNA Scientific’s expenses increased to $80,855 from $46,255.
- Net loss increased despite higher other income. The company recorded $120,469 of expected credit-loss expense and a $31,752 recovery during the quarter; net receivables increased to $839,558 after an allowance of $1.359 million.
- Foreign-currency translation loss increased to $209,908 from $39,039, materially reducing comprehensive equity. Accumulated other comprehensive losses reached $887,202.
- Operating cash usage improved to $34,442 from $116,518, while investing activities generated $24,098 compared with a $5,056 use in the prior-year quarter. Financing activities generated $24,219, principally from $26,930 of advances from directors.
Guidance, Outlook, Risks and Unusual Items
- The filing does not provide quantitative revenue, earnings or margin guidance. Management states that cash flow from operations, together with existing resources, is expected to support the current level of operations for at least the next 12 months.
- Management identifies potential liquidity pressures from hiring administrative and marketing personnel, website development, advertising and marketing expenditures, and the costs of being a public company.
- Chemrex remains the dominant revenue source and is exposed to lingering post-COVID effects on Malaysian manufacturers, including supply-chain disruption, weaker demand and shortages of inputs.
- MRNA Scientific’s screening activity was adversely affected by RNA machine breakdowns. Its future performance also depends on customer demand for diagnostic testing, regulatory compliance and qualified personnel.
- The company is exposed to Malaysian ringgit/US-dollar fluctuations, investment-market volatility, customer credit risk and supplier concentration. Three suppliers represented 52.2% of purchases during Q1 2024, and trade-payable balances to those suppliers totaled $972,718.
- Nasdaq granted an additional 180-day period, through November 4, 2024, for the company to regain compliance with the $1.00 minimum bid-price requirement under Rule 5550(a)(2). Compliance requires a closing bid price of at least $1.00 for at least 10 consecutive business days during the extension.
- MRNA Scientific issued a termination notice to a supplier concerning a contract valued at approximately $109,000. The supplier offered a without-prejudice settlement of approximately $76,000; management was evaluating the offer and legal options. No contingent asset was recorded in the filing.
- The company disclosed a strategic investment in Ascension Innovation Sdn Bhd after quarter-end; the filing refers investors to an April 18, 2024 Form 8-K for details.
- Management concluded that disclosure controls were effective, but stated that previously identified material weaknesses in internal control over financial reporting had improved and that further improvement was required. The auditor did not provide an internal-control attestation because the company is an emerging growth and smaller reporting company.
Most Important Facts for Investors to Verify
- Whether Nasdaq minimum-bid-price compliance was restored by November 4, 2024 and whether additional actions, including a reverse split, were required.
- The terms, valuation, ownership interest and strategic rationale for the Ascension Innovation investment.
- Whether RNA equipment issues were resolved and whether MRNA Scientific can restore meaningful testing revenue.
- The collectability of trade receivables, the adequacy of the $1.359 million credit-loss allowance and the resolution of the supplier dispute.
- Whether Chemrex’s narrow gross margin and customer and supplier concentrations create continuing earnings or liquidity risks.
- The nature and recurring versus nonrecurring composition of the $201,847 in other income and the effect of investment-market and foreign-exchange movements on future results.